The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
9 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,034,416 in first-year total cost, median $249,873.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IMST-K (19)]7
- Special Emphasis Panel[ZRG1 MCST-K (19)]2
Most frequent institutions
- AXOSIM, INC.1
- CYCLOPURE, INC.1
- GPB SCIENTIFIC, INC.1
- LEBRUN LABS, LLC1
- POP BIOTECHNOLOGIES, INC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Clinical Translation of Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin1SB1CA288098-01 | KUTSCHER, HILLIARD | POP BIOTECHNOLOGIES, INC, NY | $249,873 | ZRG1 |
| 2023 | Establishing industrial production of components that enable expanding accessibility of PET imaging to cancer patient population.2SB1CA192499-04 | ELIZAROV, ARKADIJ | TRACE-ABILITY, INC., CA | $156,157 | ZRG1 |
| 2022 | Clinical Trials in a Dish- hiPSC Cardiomyocyte HTS Electrophysiology System for Detecting Drug Induced Fatal Cardiac Arrhythmias2SB1ES027703-04 | BLOCK, TRAVIS JACKSON | STEMBIOSYS, INC., TX | $300,000 | ZRG1 |
| 2022 | Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing2SB1TR001270-04 | CURLEY, JABE L | AXOSIM, INC., LA | $299,226 | ZRG1 |
| 2022 | Developing a stable cell line expressing recombinant sclerostin1SB1DE031481-01 | CHEN, MO | WNT SCIENTIFIC, LLC, NY | $290,002 | ZRG1 |
| 2022 | Regulatory Readiness for a Superior Microfluidic CAR-T Therapy Cell Processing System2SB1CA228616-04 | WARD, TONY | GPB SCIENTIFIC, INC., VA | $250,000 | ZRG1 |
| 2022 | Remediation of Perfluorinated Chemicals in Water Using Novel High-Affinity Polymer Adsorbents2SB1ES029401-04A1 | BARIN, GOKHAN | CYCLOPURE, INC., IL | $203,864 | ZRG1 |
| 2022 | Electrochemical POU Water Purification System2SB1ES028171-05 | BOEHME, LINDSAYRASSOOLKHANI, ALAN | POWERTECH WATER, INC., KY | $157,292 | ZRG1 |
| 2022 | A Nonanimal Test Method to Determine the Ocular Safety of Consumer Products and Chemicals: Commercialization2SB1ES025501-04A1 | LEBRUN, STEWART | LEBRUN LABS, LLC, CA | $128,002 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.